2.1 million patient visits/2,000 physicians study
Seegnal was clinically tested in a very large scale, controlled and prospective study in Leumit Health Services (LHS), an HMO in Israel that provides coverage to ~720,000 members with ~2,000 physicians nationally.
All LHS physicians (n=1,969) and their respective patients were included in the study. The study duration was 6 months and about 2.1 million patient visits were analyzed during this period. The study included two arms of approximately equal sizes and socioeconomic status: a study group who used Seegnal and the control group that did not use Seegnal.